A biopharmaceutical company focused on proof-of-concept trials of the clinical development process.
American BriVision (Holding) Corporation (the “Company”) is offering securities through a Registration Statement that has been filed with the Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended (File No.: 333-228387) (the “Registration Statement”). A copy of the Prospectus, which is a part of the Registration Statement, may be obtained both here and on this offering's "Fundraising" page or by contacting Boustead Securities, LLC at phone: +1-949-502-4409 or email: email@example.com. No offer to buy the securities can be accepted and no part of the purchase price can be received until the effective date, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time prior to notice of its acceptance given before the effective date of the Registration Statement. This offering page and accompanying offering materials may contain forward-looking statements and information relating to the Company, its business plan and strategy, and its industry. These statements reflect management's current views with respect to future events based on information currently available and are subject to risk factors that could cause actual results to differ materially. Investors are cautioned to not rely on these forward-looking statements as they do not represent guarantees of future results or performance, which cannot be made. No person or entity assumes responsibility for the accuracy and completeness of forward-looking statements, and is under no duty to update any such statements to conform them to actual results, except as required by the applicable law, regulations or rules. There are further risks factors mentioned in the Prospectus. There is a risk of loss of the entire investment. There is no guarantee of any specific outcome. Past performance is not indicative of future results.